"Evaluation of a ""home-made"" method to determine viral genotype and characterize mutations conferring drug resistance in chronic hepatitis B patients."
Abstract: HBV breakthrough was observed only in HBeAg-positive patients and 6 of 7 patients presenting HBV breakthrough had the rtM204I/V mutations associated with 3TC resistance along with rtL180M and/or rtV173L.
Result: In the 3 other patients, the viral breakthrough was not associated with the detection of HBV resistance mutations; however the M204V mutation was detected later during the follow-up in 2 patients, (i) at 42 months, along the compensatory resistance mutations rtV173L+L180M in one patient, and (ii) at 78 months with rtL180
Prevalence and significance of Hepatitis B reverse transcriptase mutants in different disease stages of untreated patients.
Abstract: RESULTS: Among 467 consecutive eligible patients (262 chronic hepatitis B patients, 105 cirrhotic patients and 100 hepatocellular carcinoma patients), the nucleos(t)ide analogues-related mutations (rtI169T, rtV173L, rtL180M, rtA181T, rtS202C, rtM204I/V, rtN236T) were found.
Method: The primary drug resistant mutations were defin
Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.
Abstract: Among these patients, six harbored the rtM204I mutation, two harbored the rtL180M + rtM204I mutations, one harbored the rtM204I + rtM204V mutations, one harbored the rtL80I + rtM204I mutations, and one harbored the rtV173L + rtL180M + rtM204V mutations.
Abstract: This patient was
Mutations associated with occult hepatitis B virus infection result in decreased surface antigen expression in vitro.
Discussion: The G145R mutation has consistently resulted in decreased HBsAg levels and increased replication in lamivudine resistant mutants, especially among those with additional polymerase mutations, such as L180M and M204V.
Genotyping and molecular characterization of hepatitis B virus from human immunodeficiency virus-infected individuals in southern Africa.
Abstract: Prior to initiation of ART, ten percent, 3 of 29 isolates sequenced, had drug resistance mutations rtV173L, rtL180M+rtM204V and rtV214A, respectively.
Result: Three isolates had drug resistant mutations: SHH
Discussion: Even though the participants in the present study had not initiated ART, ten percent, 3 of 29 isolates sequenced, had drug resistance mutations rtV173L, rtL180M+rtM204V and rtV214A, respectively.
Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation.
Introduction: However, in the presence of rtM204I/V mutations, ETV resistance arose with the coexistence of rtI169T, rtL180M, rtT184A/F/G/I/L/S, rtS202G/I, or rtM250V mutations.
Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment.
PMID: 23197889
2012
World journal of gastroenterology
Abstract: The emergence of resistance mutations to LMV, such as rtM204V/I and/or rtL180M, were found in all patients.
Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B.
PMID: 23322992
2012
World journal of gastroenterology
Abstract: The virologic breakthrough in the clevudine group occurred in 9 (7.6%) patients at weeks 48 and 15 (12.7%) patients at week 96, which primarily corresponded to genotypic mutations of rtM204I and/or rtL180M.
HBV mutation literature information.
PMID: 
2012
Le infezioni in medicina
Browser Board
Co-occurred Entities
Filtrator
ViMRT